Balyasny Asset Management’s Rigel Pharmaceuticals RIGL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q1 | – | Sell |
-3,553
| Closed | -$53.3K | – | 2570 |
|
|
2022
Q4 | $53.3K | Buy |
3,553
+644
| +22% | +$9.66K | ﹤0.01% | 1905 |
|
|
2022
Q3 | $34K | Buy |
+2,909
| New | +$34K | ﹤0.01% | 2032 |
|
|
2022
Q2 | – | Sell |
-1,549
| Closed | -$46K | – | 2632 |
|
|
2022
Q1 | $46K | Buy |
+1,549
| New | +$46K | ﹤0.01% | 1887 |
|
|
2019
Q1 | – | Sell |
-1,152
| Closed | -$26K | – | 1480 |
|
|
2018
Q4 | $26K | Buy |
+1,152
| New | +$26K | ﹤0.01% | 1241 |
|
|
2018
Q2 | – | Sell |
-6,755
| Closed | -$239K | – | 1860 |
|
|
2018
Q1 | $239K | Buy |
+6,755
| New | +$239K | ﹤0.01% | 1507 |
|
|
2017
Q4 | – | Sell |
-2,010
| Closed | -$51K | – | 1959 |
|
|
2017
Q3 | $51K | Buy |
+2,010
| New | +$51K | ﹤0.01% | 1610 |
|
|
2016
Q4 | – | Sell |
-37,500
| Closed | -$1.38M | – | 1260 |
|
|
2016
Q3 | $1.38M | Buy |
37,500
+35,570
| +1,843% | +$1.31M | 0.01% | 647 |
|
|
2016
Q2 | $43K | Sell |
1,930
-1,916
| -50% | -$42.7K | ﹤0.01% | 950 |
|
|
2016
Q1 | $80K | Buy |
3,846
+2,314
| +151% | +$48.1K | ﹤0.01% | 1012 |
|
|
2015
Q4 | $46K | Buy |
+1,532
| New | +$46K | ﹤0.01% | 1053 |
|
|
2015
Q1 | – | Sell |
-6,377
| Closed | -$145K | – | 818 |
|
|
2014
Q4 | $145K | Sell |
6,377
-55,623
| -90% | -$1.26M | ﹤0.01% | 437 |
|
|
2014
Q3 | $1.2M | Buy |
+62,000
| New | +$1.2M | 0.01% | 418 |
|
|
2014
Q1 | – | Sell |
-133,804
| Closed | -$3.81M | – | 507 |
|
|
2013
Q4 | $3.81M | Buy |
133,804
+34,430
| +35% | +$981K | 0.05% | 285 |
|
|
2013
Q3 | $3.56M | Buy |
99,374
+39,403
| +66% | +$1.41M | 0.05% | 304 |
|
|
2013
Q2 | $2M | Buy |
+59,971
| New | +$2M | 0.03% | 331 |
|